C225 WITH CHEMORADIATION FOR POST-OP HEAD AND NECK SQUAMOUS CELL CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 采用随机分配的II期设计，对两种使用EGFR抑制剂C225联合化疗治疗高危头颈部术后患者的治疗方案进行评估。这项试验旨在确定这两种方案是否有足够的前景在随后的第三阶段研究中继续进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To evaluate, using a random assignment phase II design, two treatment regimens that utilize the EGFR inhibitor C225 in combination with chemoradiation in high-risk postoperative head and neck patients. This trial is designated to determine if either regimen is promising enough to be pursued in a subsequent phase III study.